These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1045 related articles for article (PubMed ID: 31264581)
1. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581 [TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296 [TBL] [Abstract][Full Text] [Related]
4. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A; Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046 [TBL] [Abstract][Full Text] [Related]
5. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170 [TBL] [Abstract][Full Text] [Related]
7. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689 [TBL] [Abstract][Full Text] [Related]
8. Clinical utility of multigene profiling assays in early-stage breast cancer. Chang MC; Souter LH; Kamel-Reid S; Rutherford M; Bedard P; Trudeau M; Hart J; Eisen A; Curr Oncol; 2017 Oct; 24(5):e403-e422. PubMed ID: 29089811 [TBL] [Abstract][Full Text] [Related]
9. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998 [TBL] [Abstract][Full Text] [Related]
10. Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. Edwards SJ; Barton S; Bacelar M; Karner C; Cain P; Wakefield V; Marceniuk G Health Technol Assess; 2021 Mar; 25(23):1-138. PubMed ID: 33783345 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089 [TBL] [Abstract][Full Text] [Related]
12. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation. Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. Hall PS; McCabe C; Stein RC; Cameron D J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097 [TBL] [Abstract][Full Text] [Related]
14. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group* Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310 [TBL] [Abstract][Full Text] [Related]
15. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer. Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456 [TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187 [TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Yang M; Rajan S; Issa AM Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236 [TBL] [Abstract][Full Text] [Related]
18. Impact of gene expression profiling tests on breast cancer outcomes. Marchionni L; Wilson RF; Marinopoulos SS; Wolff AC; Parmigiani G; Bass EB; Goodman SN Evid Rep Technol Assess (Full Rep); 2007 Dec; (160):1-105. PubMed ID: 18457476 [TBL] [Abstract][Full Text] [Related]
19. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816 [TBL] [Abstract][Full Text] [Related]